Atrial Fibrillation Ablation in Octogenarians: Where Do We Stand?

被引:10
|
作者
Stepanyan, Gevorg [1 ]
Gerstenfeld, Edward P. [1 ]
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
Atrial fibrillation; Ablation; Elderly; Octogenarians; Stroke; Anticoagulation; TERM CLINICAL-EFFICACY; CATHETER ABLATION; HEART-ASSOCIATION; TASK-FORCE; RISK; MANAGEMENT; SAFETY;
D O I
10.1007/s11886-013-0406-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of atrial fibrillation increases significantly with age, affecting nearly 10 % of adults greater than 80 years of age. Complications from atrial fibrillation, including stroke, also increase with age. Medical therapy includes anticoagulation, ventricular rate control, and if symptoms persist, maintenance of sinus rhythm with antiarrhythmic drugs. However, anticoagulation and antiarrhythmic therapy is often challenging in the elderly due to side effects, comorbidities, and heightened sensitivity to medications. Catheter based ablation of atrial fibrillation is an effective treatment for paroxysmal atrial fibrillation. However, the major randomized controlled trials, such as Thermocool AF and STOP-AF studies, have excluded the elderly patients. Current guidelines suggest caution when considering ablation for elderly patients due to a lack of available data. We will review recent studies that have observed the outcomes of atrial fibrillation ablation in the elderly, specifically those studies that included octogenarians.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] WHERE DO WE STAND
    不详
    [J]. MILITARY MEDICINE, 1961, 126 (01) : 66 - &
  • [32] Ablative Management of Persistent Atrial Fibrillation (PeAF) with Posterior Wall Isolation (PWI): Where Do We Stand?
    Baqal, Omar
    El Masry, Hicham Z.
    [J]. JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (07)
  • [33] Atrial Fibrillation and Anticoagulant Treatment in End-Stage Renal Disease Patients: Where Do We Stand?
    Di Lullo, Luca
    Mariani, Marco Valerio
    Ronco, Claudio
    Bellasi, Antonio
    Lavalle, Carlo
    Chimenti, Cristina
    Paoletti, Ernesto
    Ravera, Maura
    Zanella, Monica
    [J]. CARDIORENAL MEDICINE, 2022, 12 (04) : 131 - 140
  • [34] Evolution of non-pharmacological curative therapy for atrial fibrillation. Where do we stand today?
    Pappone, C
    Rosanio, S
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2003, 88 (2-3) : 135 - 142
  • [35] Left atrial appendage exclusion-Where do we stand?
    Sakellaridis, Timothy
    Argiriou, Mihalis
    Charitos, Christos
    Tsakiridis, Kosmas
    Zarogoulidis, Paul
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Machairiotis, Nikolaos
    Tsiouda, Theodora
    Arikas, Stamatis
    Mpakas, Andreas
    Beslevis, Thomas
    Koletas, Alexander
    Zarogoulidis, Konstantinos
    [J]. JOURNAL OF THORACIC DISEASE, 2014, 6 : S70 - S77
  • [36] Left Atrial Appendage Closure: Where Do We Stand Now?
    Ellenbogen, Kenneth A.
    Ashley, Phoebe
    [J]. CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2022, 36 : 25 - 26
  • [37] Gephyrin: where do we stand, where do we go?
    Fritschy, Jean-Marc
    Harvey, Robert J.
    Schwarz, Guenter
    [J]. TRENDS IN NEUROSCIENCES, 2008, 31 (05) : 257 - 264
  • [38] Catheter ablation of atrial fibrillation: do we know what we are doing?
    Katritsis, Demosthenes G.
    Camm, A. John
    [J]. EUROPACE, 2007, 9 (11): : 1002 - 1005
  • [39] Catheter Ablation of Atrial Fibrillation in Octogenarians: The Right "Medicine?"
    Kim, Michael H.
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2012, 23 (07) : 694 - 696
  • [40] Concomitant ablation of atrial fibrillation in octogenarians: an observational study
    Herko Grubitzsch
    Sven Beholz
    Pascal M Dohmen
    Simon Dushe
    Wolfgang Konertz
    [J]. Journal of Cardiothoracic Surgery, 3